UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

Clinical cancer research, 2012-08, Vol.18 (15), p.4104-4113

2012

Link zum Volltext

Verfügbarkeit prüfen

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

Cancer research (Chicago, Ill.), 2010-05, Vol.70 (9), p.3647-3656

2010

Link zum Volltext

Verfügbarkeit prüfen

CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

Clinical cancer research, 2009-06, Vol.15 (12), p.4046-4057

2009

Link zum Volltext

Verfügbarkeit prüfen

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation

Cancer biology & medicine, 2018-02, Vol.15 (1), p.39-51

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

Molecular cancer therapeutics, 2009-12, Vol.8 (12), p.3296-3306

2009

Link zum Volltext

Verfügbarkeit prüfen

A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy

Cancer research (Chicago, Ill.), 2021-12, Vol.81 (24), p.6233-6245

2021

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia

Cancer research (Chicago, Ill.), 2004-11, Vol.64 (22), p.8177-8183

2004

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

Journal of medicinal chemistry, 2010-03, Vol.53 (5), p.2000-2009

2010

Link zum Volltext

Verfügbarkeit prüfen

Novel compounds in the treatment of lung cancer: current and developing therapeutic agents

Journal of experimental pharmacology, 2011, Vol.3 (default), p.21-34

2011

Link zum Volltext

Verfügbarkeit prüfen

LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein

Oncogene, 1999-11, Vol.18 (47), p.6477-6487

1999

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1729: Discovery of a synthetic small molecule inhibitor of HSP90 for cancer therapy

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1729-1729

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 797: Discovery of a highly selective and potent small molecule inhibitor against c-MET for cancer therapy

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.797-797

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3063: Discovery of a third-generation EGFR inhibitor, which is highly selective and potent against both resistant and activating EGFR mutations for NSCLC therapy

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3063-3063

2016

Link zum Volltext

Verfügbarkeit prüfen

The radiation sensitization effect of newly discovered EGFR specific inhibitor HS-10182 in human lung cells

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20635-e20635

2016

Link zum Volltext

Verfügbarkeit prüfen

Use of a Surrogate Marker (Human Secreted Alkaline Phosphatase) to Monitor in Vivo Tumor Growth and Anticancer Drug Efficacy in Ovarian Cancer Xenografts

Gynecologic oncology, 2000-09, Vol.78 (3), p.373-379

2000

Link zum Volltext

Verfügbarkeit prüfen

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines

Cancer research (Chicago, Ill.), 2003-03, Vol.63 (6), p.1311-1316

2003

Link zum Volltext

Verfügbarkeit prüfen

Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer

Cancer research (Chicago, Ill.), 2003-03, Vol.63 (6), p.1389-1397

2003

Link zum Volltext

Verfügbarkeit prüfen

Activation of Cancer-Specific Gene Expression by the Survivin Promoter

JNCI : Journal of the National Cancer Institute, 2002-04, Vol.94 (7), p.522-528

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3744: Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3744-3744

2012

Link zum Volltext

Verfügbarkeit prüfen

Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis

Cancer research (Chicago, Ill.), 2003-08, Vol.63 (16), p.4967-4977

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C70-C70

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3249: Design and synthesis of imidazopyridine derivatives as novel HSP90 inhibitors for the treatment of cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3249-3249

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2615: Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2615-2615

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2619: Potential advantages of CUDC-101, a multi-targeted HDAC, EGFR and HER2 inhibitor, on preventing drug resistance and tumor metastasis

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2619-2619

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4469: Antitumor activity of a single small molecule agent targeting Pi3K/mTor and HDAC

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4469-4469

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(38)
Webseiten
(1)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(17)
Humans
(14)
Oncology
(14)
Animals
(13)
Female
(13)
Biological And Medical Sciences
(12)
Mice
(12)
Medical Sciences
(10)
Ovarian Neoplasms - Genetics
(7)
Xenograft Model Antitumor Assays
(7)
Tumors
(6)
Mice, Nude
(5)
Mice, Scid
(5)
Ovarian Neoplasms - Pathology
(5)
Tumor Cells, Cultured
(5)
Antineoplastic Agents
(4)
Apoptosis - Drug Effects
(4)
Cell Line, Tumor
(4)
Histone Deacetylase Inhibitors - Pharmacology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy

Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

Novel compounds in the treatment of lung cancer: current and developing therapeutic agents

LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein

Abstract 1729: Discovery of a synthetic small molecule inhibitor of HSP90 for cancer therapy

Abstract 797: Discovery of a highly selective and potent small molecule inhibitor against c-MET for cancer therapy

Abstract 3063: Discovery of a third-generation EGFR inhibitor, which is highly selective and potent against both resistant and activating EGFR mutations for NSCLC therapy

The radiation sensitization effect of newly discovered EGFR specific inhibitor HS-10182 in human lung cells

Use of a Surrogate Marker (Human Secreted Alkaline Phosphatase) to Monitor in Vivo Tumor Growth and Anticancer Drug Efficacy in Ovarian Cancer Xenografts

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines

Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer

Activation of Cancer-Specific Gene Expression by the Survivin Promoter

Abstract 3744: Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models

Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis

Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models

Abstract 3249: Design and synthesis of imidazopyridine derivatives as novel HSP90 inhibitors for the treatment of cancer

Abstract 2615: Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models

Abstract 2619: Potential advantages of CUDC-101, a multi-targeted HDAC, EGFR and HER2 inhibitor, on preventing drug resistance and tumor metastasis

Abstract 4469: Antitumor activity of a single small molecule agent targeting Pi3K/mTor and HDAC

Suchergebnisse filtern